PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could help ITP patients who failed other treatments
Disease control Recruiting nowThis study tests a drug called pirtobrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The trial has two parts: first, finding safe doses, then comparing pirtobrutinib to a placebo to see if it ra…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug aims to control rare blood disorders without lifelong steroids
Disease control Recruiting nowThis study tests a drug called tafasitamab in adults with two rare autoimmune blood disorders: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The goal is to see if it can safely raise blood cell counts and reduce the need for other treatments. About 5…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Second dose of experimental drug may help when first fails
Disease control Recruiting nowThis study tests whether a second course of ianalumab can help adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who previously responded to the drug but then stopped responding. About 60 participants will rec…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot aims to help rare bleeding disorder
Disease control Recruiting nowThis early-stage trial is testing a new drug called SHR-2173 for people with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study will enroll 10 adults to check the drug's safety and how well it works. Particip…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New shot could help raise platelet levels in chronic blood disorder
Disease control Recruiting nowThis study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if the drug can safely increase platelet counts. Abo…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo aims to boost platelets in stubborn ITP
Disease control Recruiting nowThis study tests whether adding rituximab to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite prior treatments. About 224 participants will receive either the combo or eltrombopag alone, and resea…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New IVIG treatment aims to boost platelets in ITP patients
Disease control Recruiting nowThis Phase 3 trial tests a human immunoglobulin (IVIG) given intravenously for 5 days to adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. The study will enroll 36 participants in Turkey to see if the…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Grand Shuyang Life Sciences (Chengdu) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Desperate patients get early access to experimental drug ianalumab
Disease control AVAILABLEThis program provides early access to the drug ianalumab (VAY736) for patients with serious or life-threatening conditions like immune thrombocytopenia or Sjögren's syndrome who have no other treatment options. It is not a clinical trial but a managed access program where doctors…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for ITP patients: antibody drug takes on standard therapy in head-to-head trial
Disease control Recruiting nowThis study compares two antibody drugs—daratumumab and rituximab—in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The goal is to see which drug works better at raising platelet counts and reducing bleeding risk…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for ITP patients: drug combo aims to boost platelets
Disease control Recruiting nowThis study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low or came back after steroid treatment. About 160 participants will receive either t…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for kids with Hard-to-Treat ITP: daratumumab takes on rituximab
Disease control Recruiting nowThis study tests a new drug, daratumumab, against an older one, rituximab, in children aged 6 to 17 with immune thrombocytopenia (ITP) that didn't improve with steroids. ITP causes low platelets and easy bleeding. The goal is to see which drug works better at raising platelet cou…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo aims to boost platelets in Hard-to-Treat ITP
Disease control Recruiting nowThis phase 2 trial tests whether combining rituximab with daratumumab can raise platelet counts in adults with immune thrombocytopenia (ITP) who have not responded to steroids. Twenty participants will receive one dose of rituximab and eight doses of daratumumab over eight weeks.…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New pill could help ITP patients who failed standard treatments
Disease control Recruiting nowThis phase 2 trial tests an experimental oral drug called DZD8586 (Birelentinib) in adults with primary immune thrombocytopenia (ITP) whose condition did not improve after at least one standard therapy. About 60 participants will receive one of three dose levels to see if it safe…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for kids with Hard-to-Treat blood disorder
Disease control Recruiting nowThis study tests an experimental drug called Anti-CD38 antibody in 60 children aged 6 and older who have immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The participants have not responded well to standard treatments.…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for patients with stubborn low platelet disorder?
Disease control Recruiting nowThis early-stage study tests a new drug called PRG-1801 in 6 adults with immune thrombocytopenia (ITP) that hasn't improved with standard treatments. The goal is to see if it is safe and can raise platelet counts to reduce bleeding risk. Participants receive a single infusion and…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a multiple sclerosis drug help treat a bleeding disorder?
Disease control Recruiting nowThis study tests whether adding teriflunomide (a drug used for multiple sclerosis) to standard high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, caus…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:37 UTC
-
500 kids with rare bleeding disorder to be tracked in landmark chinese study
Knowledge-focused Recruiting nowThis study follows 500 children aged 6-17 diagnosed with immune thrombocytopenia (ITP), a rare autoimmune disease that causes low platelet counts and bleeding. Researchers will collect data on symptoms, treatments, and outcomes over several years to build a model that predicts ho…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC